Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Editor’s note: Fresenius Medical Care chief medical officer Frank Maddux, MD, recently authored a paper entitled, “Doing more than caring about quality” (Seminars in Dialysis March/April 2016). In an interview with NN&I, we ask him about points made in the paper and how he believes dialysis patient care can improve.
This article is part of NN&I’s 22nd annual dialysis provider ranking. Fresenius Medical Care North America is the largest provider in the United States.
NN&I: You mention “individualized patient care is forthcoming…” Is that possible for a company that provides dialysis treatment for over 180,000 patients?
Frank Maddux, MD: There are ways to use technologies to work toward a more personalized prescription. I think we would still have standardized approaches to the treatment, but we would have opportunities to address the individual’s needs at chairside and adjust the prescription. It is a combination of technology and process, and we can individualize care even in large organizations.
NN&I: In the opening paragraphs of the Seminars article, you say “Advancing the care of patients with severe renal failure has been both a success and a failure” and we need a “roadmap to guide a fundamentally evolved approach.” What can the provider community do better?
Maddux: We have removed renal disease as a cause of death for thousands of individuals. But now, particularly with more interest in value-based care, there is an opportunity to expand beyond just the treatment. As a community, we need to be always pushing the boundaries to make a treatment better, safer. I never think that we are done. There is a lot of room for continued improvement.
Read the full story at Nephrology News